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Autoimmunity fought in the cortex
In the best-case scenario, self-attacking T cells are ousted before they have a chance to leave the 
thymus. That essential process, which eliminates autoreactive thymocytes from the get-go, is known 
to occur in the thymic medulla. Now, on page 2575, McCaughtry et al. provide solid evidence that 
this elimination also occurs in the thymic cortex.
Although immunologists have reported T cell deletion in the cortex before, their results were 
made ambiguous by the transgenic mice models they used. These mice expressed T cell receptors 
specific for a self-peptide earlier in development than they are normally expressed. One fear was that 
those T cells were being deleted before they had a chance to migrate into the medulla. To quell that 
concern, McCaughtry’s team generated a transgenic mouse in which the receptors are turned on at 
the appropriate time. Turns out, the earlier models were correct.
T cells reacting to ubiquitous self-antigens were deleted in the cortex alone, before entering the 
medulla. Furthermore, the medulla-based transcription factor AIRE, which mediates T cell deletion, 
did not seem to be required in the cortical deletions. Local dendritic cells, however, were needed. 
Without them, a large fraction of autoreactive T cell clones survived.
The locale of T cell deletion may depend on the antigen involved. Tissue-specific self-antigens 
are produced only in the medulla, whereas ubiquitous self-antigens, such as house-keeping peptides 
and the antigen recognized in the authors’ mouse model, are widespread and can be handled in the 
cortex, at the site of first encounter. Now that the question of location has been settled, future studies 
can focus on learning how cortical dendritic cells control T cells gone awry.
Death receptor chews up bone
Arthritis sufferers might find some relief in a new compound found to ease bone damage in mice. 
Bull et al. (page 2457) prevented joint erosion when they crippled a member of the TNF receptor 
superfamily, Death Receptor 3 (DR3), by blocking its ligand, TL1A.
Patients with rheumatoid arthritis are more likely to have extra copies of the gene that codes for DR3. 
A causative role for DR3 in disease pathology, however, had not been shown. Bull et al. now find that 
mice lacking DR3 are freed from the bone damage usually caused by antigen-induced arthritis. And 
blocking TL1A curtailed the bone erosion typical of collagen-induced arthritis in mice.
Back in the dish, the team investigated how this receptor–ligand pair might induce bone destruction 
in humans. They found that the addition of TL1A to ordinary monocytes from human blood enhanced 
the generation of bone-resorbing osteoclasts. Although how TL1A leads to osteoclast differentiation is not 
yet clear, its DR3 receptor is known to activate NFB, which is required for osteoclast formation.
A few stones remain unturned in the hunt for vandals, as obstructing TL1A didn’t eliminate bone 
destruction altogether. Still, the researchers point out that the anti-TL1A antibody did ameliorate 
much of the damage.
Pain in the brain
A severe and unusual disorder often confused with multiple sclerosis (MS) has now become a little 
less mysterious. On page 2473, Hinson and colleagues demonstrate how the disease’s distinguishing 
autoantibody disrupts glutamate regulation.
Neuromyelitis optica (NMO), also known as Devic’s disease, results in MS-like lesions in the 
optic nerves and along the spine. Yet unlike MS, NMO is associated with production of a specific 
autoantibody known as NMO-IgG. Clinicians use NMO-IgG to diagnose the disease, but they 
don’t know how the antibody contributes to its symptoms—sight impairment, paraplegia, and loss 
of limb, bladder, and bowel sensation. 
In 2005, the same group identified NMO-IgG’s target as aquaporin-4, a water channel 
protein concentrated in astrocyte membranes along the blood-brain barrier. However, the 
finding was somewhat perplexing because myelin damage occurs on nerve cells, not on 
astrocytes. Now the team confirms that astrocytes are indeed the relevant target, and show 
how autoantibody binding can lead to demyelination. Clue: when astrocytes hurt, their duties 
lapse, too.
When NMO-IgG binds to aquaporin-4, they show, the levels of the astrocyte glutamate 
transporter EAAT2 drop. And no transporter, no glutamate regulation. Astrocytes themselves aren’t 
sensitive to changes in glutamate levels, but neurons and oligodendrocytes are. These cells rely on 
Aquaporin-4 (red) and EAAT2 
(green) colocalize in normal spine.
Self-reactive thymocytes (green) 
are deleted in the cortex (C) before 
reaching the medulla (M).
Mice lacking DR3 (right) had 
decreased arthritic inflammation 
(black arrowheads) and bone 
erosion (blue arrowheads).